About
Onava is an AI-native biotech company in San Carlos, California, building an agentic, lab-in-the-loop antibody discovery platform that couples generative AI and ML-driven protein engineering with proprietary high-throughput functional assays to design potent, developable therapeutic antibodies against hard targets.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Onava
Onava is an AI-native biotech company in San Carlos, California, building an agentic, lab-in-the-loop antibody discovery platform that couples generative AI and ML-driven protein engineering with proprietary high-throughput functional assays to design potent, developable therapeutic antibodies against hard targets.
—
United States
BusinessLatest roundTotal raisedDate- Acrobat Genomics
Acrobat Genomics is a Stanford drug-discovery spinout and public benefit corporation at MBC BioLabs in San Carlos, CA. Its AcrobaTx Engine pairs AI-proposed gene-editor, inhibitor and protein designs with high-throughput functional screening in human cells in a closed loop. It is a prime contractor on DARPA's RIDDL program, NIH-funded, and an Illumina Accelerator 2022 company.
— - Aureka Biotechnologies
AuraIDE™, a platform for generative antibody drug discovery and functional antibody design
Series B · $200M · 2026-08
$200M - RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional methods miss, for first-in-class cancer immunotherapies
Seed · $14M · 2026-03
$14M
China
BusinessLatest roundTotal raisedDate- AIPher
AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs
Angel · 2026-09
— - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - 途深智合
AI protein design platform; conversational protein design platforms ProteinNova/ProteinEngine covering site-directed mutagenesis, enzyme engineering, de novo design, antibody structure and more
Angel · $1M · 2025-09
$1M
Europe
BusinessLatest roundTotal raisedDate- Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M
Other / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.